Literature DB >> 24904117

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.

Rui D Mendes1, Leonor M Sarmento2, Kirsten Canté-Barrett1, Linda Zuurbier1, Jessica G C A M Buijs-Gladdines1, Vanda Póvoa2, Willem K Smits1, Miguel Abecasis3, J Andres Yunes4, Edwin Sonneveld5, Martin A Horstmann6, Rob Pieters7, João T Barata2, Jules P P Meijerink1.   

Abstract

Phosphatase and tensin homolog (PTEN)-inactivating mutations and/or deletions are an independent risk factor for relapse of T-cell acute lymphoblastic leukemia (T-ALL) patients treated on Dutch Childhood Oncology Group or German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia protocols. Some monoallelic mutated or PTEN wild-type patients lack PTEN protein, implying that additional PTEN inactivation mechanisms exist. We show that PTEN is inactivated by small deletions affecting a few exons in 8% of pediatric T-ALL patients. These microdeletions were clonal in 3% and subclonal in 5% of patients. Conserved deletion breakpoints are flanked by cryptic recombination signal sequences (cRSSs) and frequently have non-template-derived nucleotides inserted in between breakpoints, pointing to an illegitimate RAG recombination-driven activity. Identified cRSSs drive RAG-dependent recombination in a reporter system as efficiently as bona fide RSSs that flank gene segments of the T-cell receptor locus. Remarkably, equivalent microdeletions were detected in thymocytes of healthy individuals. Microdeletions strongly associate with the TALLMO subtype characterized by TAL1 or LMO2 rearrangements. Primary and secondary xenotransplantation of TAL1-rearranged leukemia allowed development of leukemic subclones with newly acquired PTEN microdeletions. Ongoing RAG activity may therefore actively contribute to the acquisition of preleukemic hits, clonal diversification, and disease progression.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24904117     DOI: 10.1182/blood-2014-03-562751

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Genome editing technologies: defining a path to clinic.

Authors:  Jacqueline Corrigan-Curay; Marina O'Reilly; Donald B Kohn; Paula M Cannon; Gang Bao; Frederic D Bushman; Dana Carroll; Toni Cathomen; J Keith Joung; David Roth; Michel Sadelain; Andrew M Scharenberg; Christof von Kalle; Feng Zhang; Robert Jambou; Eugene Rosenthal; Morad Hassani; Aparna Singh; Matthew H Porteus
Journal:  Mol Ther       Date:  2015-05       Impact factor: 11.454

Review 2.  Genome folding through loop extrusion by SMC complexes.

Authors:  Iain F Davidson; Jan-Michael Peters
Journal:  Nat Rev Mol Cell Biol       Date:  2021-03-25       Impact factor: 94.444

Review 3.  Long-Range Regulation of V(D)J Recombination.

Authors:  Charlotte Proudhon; Bingtao Hao; Ramya Raviram; Julie Chaumeil; Jane A Skok
Journal:  Adv Immunol       Date:  2015-08-20       Impact factor: 3.543

Review 4.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

Review 5.  The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.

Authors:  Rui D Mendes; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

Review 6.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

Review 7.  V(D)J Recombination: Mechanism, Errors, and Fidelity.

Authors:  David B Roth
Journal:  Microbiol Spectr       Date:  2014-12

Review 8.  T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Authors:  Emma Kroeze; Jan L C Loeffen; Vera M Poort; Jules P P Meijerink
Journal:  Blood Adv       Date:  2020-07-28

9.  Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Authors:  Y Dong; F Liu; C Wu; S Li; X Zhao; P Zhang; J Jiao; X Yu; Y Ji; M Zhang
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

Review 10.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.